# EDGAR Filing Document

**Accession Number:** 0001333141
**File Stem:** 0001104659-23-017396
**Filing Date:** 2023-2
**Character Count:** 3867
**Document Hash:** a76a7ab9924309f9eae1da5da204da68
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-017396.hdr.sgml**: 20230209

**ACCESSION NUMBER**: 0001104659-23-017396

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230209

**FILED AS OF DATE**: 20230209

**DATE AS OF CHANGE**: 20230209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Fresenius Medical Care AG & Co. KGaA
- **CENTRAL INDEX KEY:** 0001333141
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **IRS NUMBER:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32749
- **FILM NUMBER:** 23604922

**BUSINESS ADDRESS:**
- **STREET 1:** ELSE-KROENER STRASSE 1
- **CITY:** BAD HOMBURG
- **STATE:** 2M
- **ZIP:** 61352
- **BUSINESS PHONE:** 011-49-6172-6090

**MAIL ADDRESS:**
- **STREET 1:** ELSE-KROENER STRASSE 1
- **CITY:** BAD HOMBURG
- **STATE:** 2M
- **ZIP:** 61352

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

For the month of February 2023

Commission file number: 001-32749

**FRESENIUS MEDICAL CARE AG & Co. KGaA**

(Translation of registrant's name into English)

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

*(Address of principal executive offices)*

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

**EXHIBITS**

The following exhibits are being furnished with this Report:

[Exhibit 99.1](tm236122d1_ex99-1.htm) [Ad-hoc statement issued on February 9, 2023.](tm236122d1_ex99-1.htm)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: February 9, 2023

Fresenius Medical Care AG & Co. KGaA, a partnership limited by shares, represented by: <br>fresenius medical care management ag, its General Partner

---

| | |
|:---|:---|
| By: | /s/ Helen Giza |
| Name: | Helen Giza |
| Title: | Chief Executive Officer, Chair of the Management Board of the General Partner and Acting Chief Financial Officer |
| By: | /s/ Dr. Katarzyna Mazur-Hofsäß |
| Name: | Dr. Katarzyna Mazur-Hofsäß |
| Title: | CEO Care Enablement and member of the Management Board of the General Partner |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm236122d1_ex99-1img01.jpg)

**Ad-hoc announcement according to Art. 17 (1) MAR**

February 9<sup>th</sup>, 2023

**<u>Fresenius Medical Care AG & Co. KGaA confirms review of the deconsolidation and a potential change of the legal form into a German stock corporation</u>**

Following press reports, Fresenius Medical Care AG & Co. KGaA ("Company") confirms that Fresenius SE & Co. KGaA, which is holding approx. 32% of the shares of the Company and which is the sole shareholder of the general partner Fresenius Medical Care Management AG, is reviewing the deconsolidation of the Company. This review includes a potential change of the legal form of the Company into a German stock corporation (Aktiengesellschaft). The review of the required measures by the Company continues and the necessary decisions of the competent bodies are still outstanding. It therefore remains open whether a deconsolidation and a change of the legal form will occur.

Contact:<br> Dr. Dominik Heger<br> EVP \| Head of Investor Relations, Strategic Development & Communications

dominik.heger@fmc-ag.com<br> P. +49 6172 609 2601